Structural requirements of peptide YY for biological activity at enteric sites

K. Yoshinaga, T. Mochizuki, N. Yanaihara, K. Oshima, M. Izukura, M. Kogire, S. Sumi, Guillermo Gomez, T. Uchida, J. C. Thompson, G. H. Greeley

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Peptide YY (PYY) is a colonic hormone consisting of 36 amino acids that is a potent inhibitor of pancreatic exocrine, gastric acid, and insulin secretion. The objective of the present experiments was to characterize the structural requirements of PYY for inhibition of pancreatic exocrine, gastric acid, and insulin secretion, using conscious dogs prepared with gastric and pancreatic fistulas. Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (400 pmol · kg-1 · h-1) inhibited cholecystokinin-8- stimulated (25 pmol · kg-1 · h-1) pancreatic exocrine secretion (P < 0.05); however, PYY-(1-10), PYY-(1-20), PYY-(6-36), PYY-(10-36), PYY-(13-36), PYY-(24-36), and PYY-(27-36) did not inhibit pancreatic exocrine secretion. Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (200, 400, 800 pmol · kg-1 · h-1) inhibited pentagastrin (0.5 μg · kg-1 · h-1) -stimulated gastric acid secretion (P < 0.05), as well as 2-deoxy- D-glucose-stimulated insulin release (75 mg/kg) in a dose-related manner. PYY-(6-36), PYY-(13-36), and [Leu31, Pro34]neuropeptide Y did not inhibit either gastric acid secretion or insulin release. In the gastric acid and insulin secretion bioassays, PYY-(1-36) was significantly more potent than PYY-(3-36) and PYY-(4-36); however, in the pancreatic exocrine secretion bioassay, the inhibitory effects of PYY-(3-36) and PYY-(1-36) did not differ significantly. PYY-(4-36) was less potent than PYY-(1-36) on pancreatic exocrine secretion. These results indicate that full expression of the inhibitory activity of PYY on gastric acid and insulin secretion requires the full sequence of PYY, whereas PYY-(3-36) is as effective as PYY-(1-36) in the inhibition of pancreatic exocrine secretion.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume263
Issue number5 26-5
StatePublished - 1992

Fingerprint

Peptide YY
Gastric Acid
Insulin
Biological Assay
Intravenous Administration
Gastric Fistula
Pancreatic Fistula
Pentagastrin
Neuropeptide Y
Deoxyglucose

Keywords

  • gastric acid secretion
  • insulin release
  • pancreatic exocrine secretion
  • peptide analogues

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Yoshinaga, K., Mochizuki, T., Yanaihara, N., Oshima, K., Izukura, M., Kogire, M., ... Greeley, G. H. (1992). Structural requirements of peptide YY for biological activity at enteric sites. American Journal of Physiology - Gastrointestinal and Liver Physiology, 263(5 26-5).

Structural requirements of peptide YY for biological activity at enteric sites. / Yoshinaga, K.; Mochizuki, T.; Yanaihara, N.; Oshima, K.; Izukura, M.; Kogire, M.; Sumi, S.; Gomez, Guillermo; Uchida, T.; Thompson, J. C.; Greeley, G. H.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 263, No. 5 26-5, 1992.

Research output: Contribution to journalArticle

Yoshinaga, K, Mochizuki, T, Yanaihara, N, Oshima, K, Izukura, M, Kogire, M, Sumi, S, Gomez, G, Uchida, T, Thompson, JC & Greeley, GH 1992, 'Structural requirements of peptide YY for biological activity at enteric sites', American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 263, no. 5 26-5.
Yoshinaga, K. ; Mochizuki, T. ; Yanaihara, N. ; Oshima, K. ; Izukura, M. ; Kogire, M. ; Sumi, S. ; Gomez, Guillermo ; Uchida, T. ; Thompson, J. C. ; Greeley, G. H. / Structural requirements of peptide YY for biological activity at enteric sites. In: American Journal of Physiology - Gastrointestinal and Liver Physiology. 1992 ; Vol. 263, No. 5 26-5.
@article{1d9491b1abc84a1e8ad1b0cd76f92fe4,
title = "Structural requirements of peptide YY for biological activity at enteric sites",
abstract = "Peptide YY (PYY) is a colonic hormone consisting of 36 amino acids that is a potent inhibitor of pancreatic exocrine, gastric acid, and insulin secretion. The objective of the present experiments was to characterize the structural requirements of PYY for inhibition of pancreatic exocrine, gastric acid, and insulin secretion, using conscious dogs prepared with gastric and pancreatic fistulas. Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (400 pmol · kg-1 · h-1) inhibited cholecystokinin-8- stimulated (25 pmol · kg-1 · h-1) pancreatic exocrine secretion (P < 0.05); however, PYY-(1-10), PYY-(1-20), PYY-(6-36), PYY-(10-36), PYY-(13-36), PYY-(24-36), and PYY-(27-36) did not inhibit pancreatic exocrine secretion. Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (200, 400, 800 pmol · kg-1 · h-1) inhibited pentagastrin (0.5 μg · kg-1 · h-1) -stimulated gastric acid secretion (P < 0.05), as well as 2-deoxy- D-glucose-stimulated insulin release (75 mg/kg) in a dose-related manner. PYY-(6-36), PYY-(13-36), and [Leu31, Pro34]neuropeptide Y did not inhibit either gastric acid secretion or insulin release. In the gastric acid and insulin secretion bioassays, PYY-(1-36) was significantly more potent than PYY-(3-36) and PYY-(4-36); however, in the pancreatic exocrine secretion bioassay, the inhibitory effects of PYY-(3-36) and PYY-(1-36) did not differ significantly. PYY-(4-36) was less potent than PYY-(1-36) on pancreatic exocrine secretion. These results indicate that full expression of the inhibitory activity of PYY on gastric acid and insulin secretion requires the full sequence of PYY, whereas PYY-(3-36) is as effective as PYY-(1-36) in the inhibition of pancreatic exocrine secretion.",
keywords = "gastric acid secretion, insulin release, pancreatic exocrine secretion, peptide analogues",
author = "K. Yoshinaga and T. Mochizuki and N. Yanaihara and K. Oshima and M. Izukura and M. Kogire and S. Sumi and Guillermo Gomez and T. Uchida and Thompson, {J. C.} and Greeley, {G. H.}",
year = "1992",
language = "English (US)",
volume = "263",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "5 26-5",

}

TY - JOUR

T1 - Structural requirements of peptide YY for biological activity at enteric sites

AU - Yoshinaga, K.

AU - Mochizuki, T.

AU - Yanaihara, N.

AU - Oshima, K.

AU - Izukura, M.

AU - Kogire, M.

AU - Sumi, S.

AU - Gomez, Guillermo

AU - Uchida, T.

AU - Thompson, J. C.

AU - Greeley, G. H.

PY - 1992

Y1 - 1992

N2 - Peptide YY (PYY) is a colonic hormone consisting of 36 amino acids that is a potent inhibitor of pancreatic exocrine, gastric acid, and insulin secretion. The objective of the present experiments was to characterize the structural requirements of PYY for inhibition of pancreatic exocrine, gastric acid, and insulin secretion, using conscious dogs prepared with gastric and pancreatic fistulas. Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (400 pmol · kg-1 · h-1) inhibited cholecystokinin-8- stimulated (25 pmol · kg-1 · h-1) pancreatic exocrine secretion (P < 0.05); however, PYY-(1-10), PYY-(1-20), PYY-(6-36), PYY-(10-36), PYY-(13-36), PYY-(24-36), and PYY-(27-36) did not inhibit pancreatic exocrine secretion. Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (200, 400, 800 pmol · kg-1 · h-1) inhibited pentagastrin (0.5 μg · kg-1 · h-1) -stimulated gastric acid secretion (P < 0.05), as well as 2-deoxy- D-glucose-stimulated insulin release (75 mg/kg) in a dose-related manner. PYY-(6-36), PYY-(13-36), and [Leu31, Pro34]neuropeptide Y did not inhibit either gastric acid secretion or insulin release. In the gastric acid and insulin secretion bioassays, PYY-(1-36) was significantly more potent than PYY-(3-36) and PYY-(4-36); however, in the pancreatic exocrine secretion bioassay, the inhibitory effects of PYY-(3-36) and PYY-(1-36) did not differ significantly. PYY-(4-36) was less potent than PYY-(1-36) on pancreatic exocrine secretion. These results indicate that full expression of the inhibitory activity of PYY on gastric acid and insulin secretion requires the full sequence of PYY, whereas PYY-(3-36) is as effective as PYY-(1-36) in the inhibition of pancreatic exocrine secretion.

AB - Peptide YY (PYY) is a colonic hormone consisting of 36 amino acids that is a potent inhibitor of pancreatic exocrine, gastric acid, and insulin secretion. The objective of the present experiments was to characterize the structural requirements of PYY for inhibition of pancreatic exocrine, gastric acid, and insulin secretion, using conscious dogs prepared with gastric and pancreatic fistulas. Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (400 pmol · kg-1 · h-1) inhibited cholecystokinin-8- stimulated (25 pmol · kg-1 · h-1) pancreatic exocrine secretion (P < 0.05); however, PYY-(1-10), PYY-(1-20), PYY-(6-36), PYY-(10-36), PYY-(13-36), PYY-(24-36), and PYY-(27-36) did not inhibit pancreatic exocrine secretion. Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (200, 400, 800 pmol · kg-1 · h-1) inhibited pentagastrin (0.5 μg · kg-1 · h-1) -stimulated gastric acid secretion (P < 0.05), as well as 2-deoxy- D-glucose-stimulated insulin release (75 mg/kg) in a dose-related manner. PYY-(6-36), PYY-(13-36), and [Leu31, Pro34]neuropeptide Y did not inhibit either gastric acid secretion or insulin release. In the gastric acid and insulin secretion bioassays, PYY-(1-36) was significantly more potent than PYY-(3-36) and PYY-(4-36); however, in the pancreatic exocrine secretion bioassay, the inhibitory effects of PYY-(3-36) and PYY-(1-36) did not differ significantly. PYY-(4-36) was less potent than PYY-(1-36) on pancreatic exocrine secretion. These results indicate that full expression of the inhibitory activity of PYY on gastric acid and insulin secretion requires the full sequence of PYY, whereas PYY-(3-36) is as effective as PYY-(1-36) in the inhibition of pancreatic exocrine secretion.

KW - gastric acid secretion

KW - insulin release

KW - pancreatic exocrine secretion

KW - peptide analogues

UR - http://www.scopus.com/inward/record.url?scp=0026447128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026447128&partnerID=8YFLogxK

M3 - Article

VL - 263

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 5 26-5

ER -